{
  "issued_date": "2013-03-12", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON249611", 
  "doc_details": {
    "Type": "Medical Device Alert", 
    "Series No": "MDA/2013/010", 
    "Audience": "Healthcare professionals", 
    "Published": "12 March 2013", 
    "Format": "Electronic only", 
    "Size": "A4", 
    "Pages": "5", 
    "Price": "Free", 
    "ISBN/ISSN": "", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "Field Safety Notice", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/fsn/documents/fieldsafetynotice/con222579.pdf", 
      "filename": "downloads/55b6f31f32ae3df4eabc85951d54a767c9f04016/con222579.pdf", 
      "original_filename": "con222579.pdf"
    }
  ], 
  "body": "## Device\n\nMetal-on-metal (MoM) total hip replacements:\n\nADEPT\u00ae 12/14 modular head\n\nManufactured by Finsbury Orthopaedics Ltd.\n\nAll lots.\n\nThe ADEPT\u00ae 12/14 modular head used in MoM total hip arthroplasty, manufactured by Finsbury Orthopaedics Ltd. \u00a0Finsbury was acquired by DePuy in December 2009. This device was commercially available from Finsbury or DePuy from 2004 to September 2011.\n\nNote: This alert does not apply to ADEPT\u00ae hip resurfacing femoral components, which are not implanted in total hip arthroplasty procedures.\n\n## Problem\n\nHigher than expected revision rate for the ADEPT\u00ae 12/14 modular head components when used in a total hip arthroplasty.\n\nAnalysis of data from the National Joint Registry (NJR) for England and Wales since 11 November 2012 has shown a higher than expected cumulative revision rate for the ADEPT\u00ae 12/14 modular head when used in conventional total hip arthroplasty (12.1% at seven years).\n\nFurther information on the revision rates for specific stems used with the ADEPT\u00ae 12/14 modular head can be found in DePuy\u2019s [ASSET_TAG](#ASSET0) recalling the affected modular heads (issued 15 January 2013).\n\n## Action  \n  \n  * Do not implant ADEPT\u00ae 12/14 modular head devices.  \n  * Return all affected devices to DePuy International Ltd.  \n  * Follow up both symptomatic and asymptomatic patients implanted with these devices in line with recommendations in the table on page\u00a02.  \n  * Report all adverse incidents to the MHRA and DePuy International.  \n  \n### Action by  \n  \n  * Medical directors.  \n  * Orthopaedic departments.  \n  * Orthopaedic surgeons.  \n  * Staff involved in the management of patients with joint replacement implants.  \n  \nManagement recommendations for patients with stemmed MoM total hip replacements \u2013 femoral head diameter \u226536mm (extracted from the table within the MHRA\u2019s [MDA/2012/036](http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON155761))  \n  \n\u00a0 |   | Stemmed MoM total hip replacements \u2013 femoral head diameter \u226536mm |   \n\u00a0 |   |  Symptomatic patients  |   | Asymptomatic patients |   \nPatient follow-up |   | Annually for the life of the implant |   | Annually for the life of the implant |   \nImaging: MARS MRI or ultrasound |   | Recommended in all cases |   | Recommended if blood metal ion levels rising |   \n1st blood metal ion level test |   | Yes |   | Yes |   \nResults of 1st blood metal ion level test |   | Blood metal ion level >7ppb indicates potential for soft tissue reaction |   | If blood metal ion level >7ppb then second blood test required 3 months later |   \n2nd blood metal ion level test |   | Yes \\- 3 months after 1st blood test \u00a0if\u00a0 result was >7ppb |   | Yes \\- 3 months after 1st\u00a0 blood test if result was \u00a0>7ppb |   \nResults of 2nd blood metal ion level test |   | Blood metal ion level >7ppb indicates potential for soft tissue reaction especially if greater than previously |   | If blood metal ion levels rising - further investigation required including imaging |   \nConsider need for revision |   | If \u00a0imaging is abnormal and/or blood metal ion levels rising |   | If \u00a0imaging is abnormal and/or blood metal ion levels rising | \n\nTable footnotes:  \n  \n  * Blood metal ion testing to be in whole blood.  \n  * 7 parts per billion (ppb) equals 119 nmol/l cobalt or 134.5 nmol/l chromium.  \n  \nMeasurements of cobalt or chromium ions should be carried out:  \n  \n  * in England, Northern Ireland or Wales, by laboratories participating in the Trace Elements  \nExternal Quality Assessment Scheme (TEQAS)\u00a0 -\u00a0 <http://www.sas-centre.org/home.html>  \n  * in Scotland, by the Scottish Trace Element and Micronutrient Reference Laboratories -  \nScottish Trace Element and Micronutrient Reference Laboratory\u00a0 -\u00a0 <http://www.trace-elements.co.uk/>  \n  \nGuidance notes:  \n  \n  * On the basis of current knowledge, this chart has been produced as a guide to the management of these patients. It will not necessarily cover all clinical situations and each patient must be judged individually.  \n  * MARS MRI scans (or ultrasound scans) should carry more weight in decision making than blood ion levels alone.  \n  * Patients with muscle or bone damage on MARS MRI are those of most concern. A fluid collection alone around the joint in an asymptomatic patient, unless it is very large can be safely observed with interval scanning.  \n  * Local symptoms include pain and limping.  \n  \n## Distribution\n\nThis MDA has been sent to:  \n  \n  * NHS trusts in England (chief executives)  \n  * Care Quality Commission (CQC) (headquarters) for information  \n  * HSC trusts in Northern Ireland (chief executives)  \n  * NHS boards in Scotland (equipment coordinators)  \n  * Local authorities in Scotland (equipment coordinators)  \n  * NHS boards and trusts in Wales (chief executives)  \n  * Primary care trusts in England (chief executives)  \n  \n### Onward distribution\n\nPlease bring this notice to the attention of relevant employees in your establishment.\u00a0Below is a suggested list of recipients.\n\nTrusts  \nCAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:  \n  \n  * Clinical governance leads  \n  * Medical directors  \n  * Nursing executive directors  \n  * Orthopaedic departments  \n  * Orthopaedic outpatient clinics  \n  * Orthopaedic surgeons  \n  * Outpatient theatre nurses  \n  * Pathologists  \n  * Procurement managers  \n  * Purchasing managers  \n  * Radiology departments  \n  * Radiology directors  \n  * Risk managers  \n  * Theatre managers  \n  \nPrimary care trusts  \nCAS liaison officers for onward distribution to all relevant staff including:  \n  \n  * Directors of public health  \n  * General practitioners (for information only)  \n  * NHS walk-in centres (for information only)  \n  \n### Independent distribution\n\nEstablishments registered with the Care Quality Commission (CQC) (England only)  \nThis alert should be read by:  \n  \n  * Hospitals in the independent sector  \n  * Independent treatment centres  \n  * Private medical practitioners  \n  \nPlease note: CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health\u2019s Central Alerting System (CAS) by sending an email to: [safetyalerts@dh.gsi.gov.uk](mailto:safetyalerts@dh.gsi.gov.uk) and requesting this facility.\n\n## Manufacturer Contact\n\nDePuy International Ltd  \nPaul Arnott  \nComplaints & Vigilance Manager  \nSt Anthony\u2019s Road  \nLeeds  \nLS11 8DT\n\nTel:\u00a0\u00a0\u00a0 07771 971 930  \nFax:\u00a0\u00a0 0113 387 6087\n\nEmail: [parnott@its.jnj.com](mailto:parnott@its.jnj.com)\n\n## Feedback\n\nIf you have any comments or feedback on this Medical Device Alert please email us at: [dts@mhra.gsi.gov.uk](mailto:dts@mhra.gsi.gov.uk)\n\n## England\n\nIf you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2013/010 or 2013/001/008/291/010  \n  \nTechnical aspects  \nMiss Feza Haque and Dr Crina Cacou  \nMedicines & Healthcare products Regulatory Agency  \nFloor 4  \n151 Buckingham Palace Road  \nLondon SW1W 9SZ  \nTel: 020 3080 7066 / 7338  \nFax: 020 8754 3965  \nEmail: [feza.haque@mhra.gsi.gov.uk](mailto:feza.haque@mhra.gsi.gov.uk) or [crina.cacou@mhra.gsi.gov.uk](mailto:crina.cacou@mhra.gsi.gov.uk)  \nClinical aspects  \nDr Nicola Lennard  \nMedicines & Healthcare products Regulatory Agency  \nFloor 4  \n151 Buckingham Palace Road  \nLondon SW1W 9SZ  \nTel: 020 3080 7126  \nFax: 020 8754 3965  \nEmail: [nicola.lennard@mhra.gsi.gov.uk](mailto:nicola.lennard@mhra.gsi.gov.uk)\n\n### How to report adverse incidents\n\nPlease report via our website: [Reporting adverse incidents involving medical devices](http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm)  \nFurther information about CAS can be found [on the CAS website](https://www.cas.dh.gov.uk/Home.aspx) (external link)\n\n## Northern Ireland\n\nAlerts in Northern Ireland will continue to be distributed via the NI SABS system.\n\nEnquiries and adverse incident reports in Northern Ireland should be addressed to:\n\nNorthern Ireland Adverse Incident Centre  \nHealth Estates Investment Group  \nRoom 17  \nAnnex 6  \nCastle Buildings  \nStormont Estate  \nDundonald BT4 3SQ\n\nTel: 02890 523 704  \nFax: 02890 523 900  \nEmail: [NIAIC@dhsspsni.gov.uk](mailto:NIAIC@dhsspsni.gov.uk)\n\n### How to report adverse incidents in Northern Ireland\n\nPlease report directly to NIAIC, further information can be found on the [NIAIC website](http://www.dhsspsni.gov.uk/niaic) (external link)  \nFurther information about SABS can be found [on the SABS website](http://sabs.dhsspsni.gov.uk/)(external link)\n\n## Scotland\n\nEnquiries and adverse incident reports in Scotland should be addressed to:\n\nIncident Reporting and Investigation Centre  \nHealth Facilities Scotland  \nNHS National Services Scotland  \nGyle Square  \n1 South Gyle Crescent  \nEdinburgh EH12 9EB\n\nTel: 0131 275 7575  \nFax: 0131 314 0722\n\nEmail: [nss.iric@nhs.net](mailto:nss.iric@nhs.net)\n\n[Health Facilities Scotland Incident Reporting and Investigation Centre (IRIC)Health Facilities Scotland Incident Reporting and Investigation Centre (IRIC)](http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/) (external link)\n\n## Wales\n\nEnquiries in Wales should be addressed to:  \n  \nImproving Patient Safety Team  \nMedical Directorate  \nWelsh Government  \nCathays Park  \nCardiff CF10 3NQ\n\nTel: 029 2082 3922  \nEmail: [Haz-Aic@wales.gsi.gov.uk](mailto:Haz-Aic@wales.gsi.gov.uk)\n", 
  "raw_html": "<div id=\"inner_tab_content\">\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t<h2 class=\"sw\">Device</h2><div class=\"content_section active_content_section\" id=\"Device\">\r\n\t\t\t\t\t\t\t\t<p><span>Metal-on-metal (MoM) total hip replacements:</span></p>\n\n<p><span>ADEPT&#174; 12/14 modular head</span></p>\n\n<p><span>Manufactured by Finsbury Orthopaedics Ltd.</span></p>\n\n<p><span>All lots.</span></p>\n\n<p>The ADEPT&#174; 12/14 modular head used in MoM total hip arthroplasty, manufactured by Finsbury Orthopaedics Ltd. &#160;Finsbury was acquired by DePuy in December 2009. This device was commercially available from Finsbury or DePuy from 2004 to September 2011.</p>\n\n<p>Note: This alert does not apply to ADEPT&#174; hip resurfacing femoral components, which are not implanted in total hip arthroplasty procedures.</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Problem</h2><div class=\"content_section\" id=\"Problem\">\r\n\t\t\t\t\t\t\t\t<p>Higher than expected revision rate for the ADEPT&#174; 12/14 modular head components when used in a total hip arthroplasty.</p>\n\n<p>Analysis of data from the National Joint Registry (NJR) for England and Wales since 11 November 2012 has shown a higher than expected cumulative revision rate for the ADEPT<sup>&#174;</sup> 12/14 modular head when used in conventional total hip arthroplasty (12.1% at seven years).</p>\n\n<p>Further information on the revision rates for specific stems used with the ADEPT<sup>&#174;</sup> 12/14 modular head can be found in DePuy&#8217;s <a href=\"#ASSET0\">ASSET_TAG</a> recalling the affected modular heads (issued 15 January 2013).</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Action</h2><div class=\"content_section\" id=\"Action\">\r\n\t\t\t\t\t\t\t\t<ul>\n<li>Do not implant ADEPT<sup>&#174;</sup> 12/14 modular head devices.</li>\n\n<li>Return all affected devices to DePuy International Ltd.</li>\n\n<li>Follow up both symptomatic and asymptomatic patients implanted with these devices in line with recommendations in the table on page&#160;2.</li>\n\n<li>Report all adverse incidents to the MHRA and DePuy International.</li>\n</ul>\n\n<h3>Action by</h3>\n\n<ul>\n<li>Medical directors.</li>\n\n<li>Orthopaedic departments.</li>\n\n<li>Orthopaedic surgeons.</li>\n\n<li>Staff involved in the management of patients with joint replacement implants.</li>\n</ul>\n\n<p><span>Management recommendations for patients with stemmed MoM total hip replacements &#8211; femoral head diameter &#8805;36mm (extracted from the table within the MHRA&#8217;s <a href=\"http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON155761\" target=\"_blank\">MDA/2012/036</a>)</span></p>\n\n<div align=\"center\">\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tr>\n<td width=\"165\">&#160;</td>\n<td width=\"358\" colspan=\"2\"><span>Stemmed MoM total hip replacements &#8211; femoral head diameter &#8805;36mm</span></td>\n</tr>\n\n<tr>\n<td width=\"165\">&#160;</td>\n<td width=\"178\">\n <span>Symptomatic</span>\n\n <span>patients</span>\n</td>\n<td width=\"180\"><span>Asymptomatic patients</span></td>\n</tr>\n\n<tr>\n<td width=\"165\"><span>Patient follow-up</span></td>\n<td width=\"178\">Annually for the life of the implant</td>\n<td width=\"180\">Annually for the life of the implant</td>\n</tr>\n\n<tr>\n<td width=\"165\"><span>Imaging: MARS MRI or ultrasound</span></td>\n<td width=\"178\">Recommended in all cases</td>\n<td width=\"180\">Recommended if blood metal ion levels rising</td>\n</tr>\n\n<tr>\n<td width=\"165\"><span>1<sup>st</sup> blood metal ion level test</span></td>\n<td width=\"178\"><span>Yes</span></td>\n<td width=\"180\"><span>Yes</span></td>\n</tr>\n\n<tr>\n<td width=\"165\"><span>Results of 1<sup>st</sup> blood metal ion level test</span></td>\n<td width=\"178\">Blood metal ion level &gt;7ppb indicates potential for soft tissue reaction</td>\n<td width=\"180\">If blood metal ion level &gt;7ppb then second blood test required 3 months later</td>\n</tr>\n\n<tr>\n<td width=\"165\"><span>2<sup>nd</sup> blood metal ion level test</span></td>\n<td width=\"178\"><span>Yes</span> - 3 months after 1<sup>st</sup> blood test &#160;if&#160; result was &gt;7ppb</td>\n<td width=\"180\"><span>Yes</span> - 3 months after 1<sup>st&#160; </sup>blood test if result was &#160;&gt;7ppb</td>\n</tr>\n\n<tr>\n<td width=\"165\"><span>Results of 2<sup>nd</sup> blood metal ion level test</span></td>\n<td width=\"178\">Blood metal ion level &gt;7ppb indicates potential for soft tissue reaction especially if greater than previously</td>\n<td width=\"180\">If blood metal ion levels rising - further investigation required including imaging</td>\n</tr>\n\n<tr>\n<td width=\"165\"><span>Consider need for revision</span></td>\n<td width=\"178\">If &#160;imaging is abnormal and/or blood metal ion levels rising</td>\n<td width=\"180\">If &#160;imaging is abnormal and/or blood metal ion levels rising</td>\n</tr>\n</table>\n</div>\n\n<p>Table footnotes:</p>\n\n<ul>\n<li>Blood metal ion testing to be in whole blood.</li>\n\n<li>7 parts per billion (ppb) equals 119 nmol/l cobalt or 134.5 nmol/l chromium.</li>\n</ul>\n\n<p>Measurements of cobalt or chromium ions should be carried out:</p>\n\n<ul>\n<li>in England, Northern Ireland or Wales, by laboratories participating in the Trace Elements<br>\nExternal Quality Assessment Scheme (TEQAS)&#160; -&#160; <a href=\"http://www.sas-centre.org/home.html\" target=\"_blank\">http://www.sas-centre.org/home.html</a></li>\n\n<li>in Scotland, by the Scottish Trace Element and Micronutrient Reference Laboratories -<br>\nScottish Trace Element and Micronutrient Reference Laboratory&#160; -&#160; <a href=\"http://www.trace-elements.co.uk/\" target=\"_blank\">http://www.trace-elements.co.uk/</a></li>\n</ul>\n\n<p>Guidance notes:</p>\n\n<ul>\n<li>On the basis of current knowledge, this chart has been produced as a guide to the management of these patients. It will not necessarily cover all clinical situations and each patient must be judged individually.</li>\n\n<li>MARS MRI scans (or ultrasound scans) should carry more weight in decision making than blood ion levels alone.</li>\n\n<li>Patients with muscle or bone damage on MARS MRI are those of most concern. A fluid collection alone around the joint in an asymptomatic patient, unless it is very large can be safely observed with interval scanning.</li>\n\n<li>Local symptoms include pain and limping.</li>\n</ul>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Distribution</h2><div class=\"content_section\" id=\"Distribution\">\r\n\t\t\t\t\t\t\t\t<p>This MDA has been sent to:</p>\n\n<ul>\n<li>NHS trusts in England (chief executives)</li>\n\n<li>Care Quality Commission (CQC) (headquarters) for information</li>\n\n<li>HSC trusts in Northern Ireland (chief executives)</li>\n\n<li>NHS boards in Scotland (equipment coordinators)</li>\n\n<li>Local authorities in Scotland (equipment coordinators)</li>\n\n<li>NHS boards and trusts in Wales (chief executives)</li>\n\n<li>Primary care trusts in England (chief executives)</li>\n</ul>\n\n<h3>Onward distribution</h3>\n\n<p>Please bring this notice to the attention of relevant employees in your establishment.&#160;Below is a suggested list of recipients.</p>\n\n<p><span>Trusts</span><br>\nCAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:</p>\n\n<ul>\n<li>Clinical governance leads</li>\n\n<li>Medical directors</li>\n\n<li>Nursing executive directors</li>\n\n<li>Orthopaedic departments</li>\n\n<li>Orthopaedic outpatient clinics</li>\n\n<li>Orthopaedic surgeons</li>\n\n<li>Outpatient theatre nurses</li>\n\n<li>Pathologists</li>\n\n<li>Procurement managers</li>\n\n<li>Purchasing managers</li>\n\n<li>Radiology departments</li>\n\n<li>Radiology directors</li>\n\n<li>Risk managers</li>\n\n<li>Theatre managers</li>\n</ul>\n\n<p><span>Primary care trusts</span><br>\nCAS liaison officers for onward distribution to all relevant staff including:</p>\n\n<ul>\n<li>Directors of public health</li>\n\n<li>General practitioners (for information only)</li>\n\n<li>NHS walk-in centres (for information only)</li>\n</ul>\n\n<h3>Independent distribution</h3>\n\n<p><span>Establishments registered with the Care Quality Commission (CQC) (England only)</span><br>\nThis alert should be read by:</p>\n\n<ul>\n<li>Hospitals in the independent sector</li>\n\n<li>Independent treatment centres</li>\n\n<li>Private medical practitioners</li>\n</ul>\n\n<p><span>Please note: </span>CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health&#8217;s Central Alerting System (CAS) by sending an email to: <a href=\"mailto:safetyalerts@dh.gsi.gov.uk\" added=\"null\">safetyalerts@dh.gsi.gov.uk</a> and requesting this facility.</p>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Manufacturer Contact</h2><div class=\"content_section\" id=\"Manufacturer Contact\">\r\n\t\t\t\t\t\t\t\t<p><span>DePuy International Ltd<br>\n</span>Paul Arnott<br>\nComplaints &amp; Vigilance Manager<br>\nSt Anthony&#8217;s Road<br>\nLeeds<br>\nLS11 8DT</p>\n\n<p>Tel:&#160;&#160;&#160; 07771 971 930<br>\nFax:&#160;&#160; 0113 387 6087</p>\n\nEmail: <a href=\"mailto:parnott@its.jnj.com\">parnott@its.jnj.com</a>\r\n\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Feedback</h2><div class=\"content_section\" id=\"Feedback\">\r\n\t\t\t\t\t\t\t\tIf you have any comments or feedback on this Medical Device Alert please email us at: <a href=\"mailto:dts@mhra.gsi.gov.uk\" added=\"null\">dts@mhra.gsi.gov.uk</a>\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t<h2 class=\"sw\">England</h2><div class=\"content_section\" id=\"England\">\r\n\t\t\t\t\t\t\t\t\t<p>If you are in England, please send enquiries about this notice to the MHRA, quoting reference number <span>MDA/2013/010</span> or <span>2013/001/008/291/010</span><br>\n<br>\n<span>Technical aspects</span><br>\nMiss Feza Haque and Dr Crina Cacou<br>\nMedicines &amp; Healthcare products Regulatory Agency<br>\nFloor 4<br>\n151 Buckingham Palace Road<br>\nLondon SW1W 9SZ<br>\nTel: 020 3080 7066 / 7338<br>\nFax: 020 8754 3965<br>\nEmail: <a href=\"mailto:feza.haque@mhra.gsi.gov.uk\">feza.haque@mhra.gsi.gov.uk</a> or <a href=\"mailto:crina.cacou@mhra.gsi.gov.uk\">crina.cacou@mhra.gsi.gov.uk</a><br>\n<span>Clinical aspects</span><br>\nDr Nicola Lennard<br>\nMedicines &amp; Healthcare products Regulatory Agency<br>\nFloor 4<br>\n151 Buckingham Palace Road<br>\nLondon SW1W 9SZ<br>\nTel: 020 3080 7126<br>\nFax: 020 8754 3965<br>\nEmail: <a href=\"mailto:nicola.lennard@mhra.gsi.gov.uk\">nicola.lennard@mhra.gsi.gov.uk</a></p>\n\n<h3>How to report adverse incidents</h3>\n\n<p>Please report via our website: <a href=\"http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm\" added=\"null\">Reporting adverse incidents involving medical devices</a><br>\nFurther information about CAS can be found <a href=\"https://www.cas.dh.gov.uk/Home.aspx\" target=\"_blank\" added=\"null\">on the CAS website</a> (external link)</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Northern Ireland</h2><div class=\"content_section\" id=\"Northern Ireland\">\r\n\t\t\t\t\t\t\t\t\t<p>Alerts in Northern Ireland will continue to be distributed via the NI SABS system.</p>\n\n<p>Enquiries and adverse incident reports in Northern Ireland should be addressed to:</p>\n\n<p>Northern Ireland Adverse Incident Centre<br>\nHealth Estates Investment Group<br>\nRoom 17<br>\nAnnex 6<br>\nCastle Buildings<br>\nStormont Estate<br>\nDundonald BT4 3SQ</p>\n\n<p>Tel: 02890 523 704<br>\nFax: 02890 523 900<br>\nEmail: <a href=\"mailto:NIAIC@dhsspsni.gov.uk\" added=\"null\">NIAIC@dhsspsni.gov.uk</a></p>\n\n<h3>How to report adverse incidents in Northern Ireland</h3>\n\n<p>Please report directly to NIAIC, further information can be found on the <a href=\"http://www.dhsspsni.gov.uk/niaic\" added=\"null\">NIAIC website</a> (external link)<br>\nFurther information about SABS can be found <a href=\"http://sabs.dhsspsni.gov.uk/\" added=\"null\">on the SABS website</a>(external link)</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Scotland</h2><div class=\"content_section\" id=\"Scotland\">\r\n\t\t\t\t\t\t\t\t\t<p>Enquiries and adverse incident reports in Scotland should be addressed to:</p>\n\n<p>Incident Reporting and Investigation Centre<br>\nHealth Facilities Scotland<br>\nNHS National Services Scotland<br>\nGyle Square<br>\n1 South Gyle Crescent<br>\nEdinburgh EH12 9EB</p>\n\n<p>Tel: 0131 275 7575<br>\nFax: 0131 314 0722</p>\n\n<p>Email: <a href=\"mailto:nss.iric@nhs.net\" added=\"null\">nss.iric@nhs.net</a></p>\n\n<p><a href=\"http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/\" target=\"_blank\" added=\"null\">Health Facilities Scotland Incident Reporting and Investigation Centre (IRIC)<font>Health Facilities Scotland Incident Reporting and Investigation Centre (IRIC)</font></a> (external link)</p>\r\n\t\t\t\t\t\t\t\t</div>\r\n<h2 class=\"sw\">Wales</h2><div class=\"content_section\" id=\"Wales\">\r\n\t\t\t\t\t\t\t\t\t<p>Enquiries in Wales should be addressed to:<br>\n<br>\nImproving Patient Safety Team<br>\nMedical Directorate<br>\nWelsh Government<br>\nCathays Park<br>\nCardiff CF10 3NQ</p>\n\n<p>Tel: 029 2082 3922<br>\nEmail: <a href=\"mailto:Haz-Aic@wales.gsi.gov.uk\" added=\"null\">Haz-Aic@wales.gsi.gov.uk</a></p>\r\n\t\t\t\t\t\t\t\t</div>\r\n</div>\r\n\t\t\t", 
  "title": "Medical Device Alert: ADEPT\u00ae 12/14 modular head hip components manufactured by Finsbury Orthopaedics Ltd (MDA/2013/010)", 
  "alert_type": [
    "devices"
  ], 
  "medical_specialism": [
    "general-practice", 
    "orthopaedics", 
    "radiology"
  ]
}